Abbott Laboratories vs. Amylyx Pharmaceuticals, Inc. Common Stock
ABT
Abbott Laboratories
$101.29 +0.22%
VS AMLXAmylyx Pharmaceuticals, Inc. Common Stock
$29.49 -2.16%
Abbott Laboratories (ABT) comes out ahead, leading on 5 of 7 compared factors.
Size & Scale
| ABT | AMLX | |
|---|---|---|
| Market Cap | $175.27 billion | $3.76 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-152,092,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | AMLX | |
|---|---|---|
| P/E Ratio | 32.78 | — |
| Price / Book | 3.39 | 15.74 |
| Price / Sales | 3.76 | — |
ABT leads on 1 of 1 valuation factors.
Profitability
| ABT | AMLX | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | -63.59% |
ABT leads on 1 of 1 profitability factors.
Dividend
| ABT | AMLX | |
|---|---|---|
| Dividend Yield | 2.49% | 5.69% |
| Payout Ratio | 81.55 | — |
AMLX leads on 1 of 1 dividend factors.
Risk & Sentiment
| ABT | AMLX | |
|---|---|---|
| Short Interest | 0.57% | 0.00% |
AMLX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, AMLX overview, AMLX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.